Insights Into Chronic Lymphocytic Leukemia (CLL) 2024
Perspectives of community physicians on the treatment of CLL
Faculty Chair
Amitkumar Mehta, MD
University of Alabama, Birmingham, AL, USA
Faculty Chair
John Burke, MD
Rocky Mountain Cancer Centers, Aurora, CO, USA
Faculty Chair
Jacqueline Brown, MD
Winship Cancer Institute, Atlanta, GA, USA
Faculty Chair
Mazyar Shadman, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
Faculty Chair
Marc Hoffmann, MD
University of Kansas Medical Center, Kansas City, KS, USA
Faculty Chair
Nirav Shah, MD
Stanford University School of Medicine, Stanford, CA, USA
Faculty Chair
Catherine Coombs, MD
University of California, Irvine, CA, USA
Faculty Chair
Chaitra S. Ujjani, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
More Information
- San Diego, CA
- California
More Information
- Seattle, WA
- Idaho, Montana, Northern California, Oregon, Washington, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of CLL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region